Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6 %: etiology of bacterial conjunctivitis and antibacterial susceptibility profile - Haas, W (Clin Ophthalmol, 2011)
et al.